At the news
? BULLISHIMPACT 6/10 8-K filed Nov 12, 2026 at 07:19 ET
Twist Bioscience reported fiscal Q4 2026 revenue of $126.6M (+28% YoY), above the $123.6M consensus, and achieved positive adjusted EBITDA of $2.2M for the first time. The company guided FY2027 revenue to $550M-$560M (21% YoY growth at the midpoint) and expects continued adjusted EBITDA profitability. Net loss narrowed to $20.6M from $27.1M a year ago.
- Q4 FY2026 revenue $126.6M, up 28% YoY from $99.0M, above consensus of $123.6M
- Full year FY2026 revenue $459.4M, up 22% YoY from $376.6M
- Q4 adjusted EBITDA positive at $2.2M vs $(7.8M) a year ago, achieving breakeven milestone
- FY2027 revenue guidance $550M-$560M, 21% YoY growth at midpoint
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access